Strahlentherapie des Mediastinalen Hodgkin-Lymphoms

Literaturverzeichnis
Thuret, I., Demeocq, F., Leverger, G., Delsol, G., and Landman-Parker, J. (2003). Lymphocyte-predominant
Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French
Society of Pediatric Oncology. J Clin Oncol 21, 2948-2952.
Peters, M. (1950). A study of survivals in Hodgkin's disease treated radiologically. Am J Roentgenol Radium
Ther Nucl Med 63, 299-311.
Polednik, M., Abo Madyan, Y., Schneider, F., Wolff, D., Bannach, B., Lambrecht, U., Wallin, A., Cwiekala, M.,
Maurer, K., Reif, F., Lohr, F., and Wenz, F. (2007). Evaluation of calculation algorithms implemented in
different commercial planning systems on an anthropomorphic breast phantom using film dosimetry.
Strahlenther Onkol 183, 667-672.
Potters, L., Steinberg, M., Wallner, P., and Hevezi, J. (2003). How one defines intensity-modulated radiation
therapy. Int J Radiat Oncol Biol Phys 56, 609-610.
Proctor, S.J., Rueffer, J.U., Angus, B., Breuer, K., Flechtner, H., Jarrett, R., Levis, A., Taylor, P., and Tirelli, U.
(2002). Hodgkin's disease in the elderly: current status and future directions. Ann Oncol 13 Suppl 1, 133-137.
Punnett, A., Tsang, R.W., and Hodgson, D.C. (2010). Hodgkin lymphoma across the age spectrum:
epidemiology, therapy, and late effects. Semin Radiat Oncol 20, 30-44.
Pusey, W.E. (1902). Cases of Sarcoma and of Hodgkin's Disease Treated by Eposures to x-rays - a Preliminary
Record. JAMA 38, 166-169.
Radford, J.A., and Crowther, D. (1991). Treatment of relapsed Hodgkin's disease using a weekly chemotherapy
of short duration: results of a pilot study in 20 patients. Ann Oncol 2, 505-509.
Reed, D.M. (1902). On the pathological changes in Hodgkin's disease, with special reference to its relation to
tuberculosis. Johns Hopkins Hosp Rep 10, 133-196.
Rehwald, U., Schulz, H., Reiser, M., Sieber, M., Staak, J.O., Morschhauser, F., Driessen, C., Rudiger, T.,
Muller-Hermelink, K., Diehl, V., and Engert, A. (2003). Treatment of relapsed CD20+ Hodgkin lymphoma with
the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German
Hodgkin Lymphoma Study Group. Blood 101, 420-424.
Reymen, B., Spiessens, S., and Lievens, Y. (2010). Radiotherapy in early stage Hodgkin's lymphoma: The
importance of volume and treatment position. Radiother Oncol 95, 225-228.
Rice, D.C., Smythe, W.R., Liao, Z., Guerrero, T., Chang, J.Y., McAleer, M.F., Jeter, M.D., Correa, A.,
Vaporciyan, A.A., Liu, H.H., Komaki, R., Forster, K.M., and Stevens, C.W. (2007). Dose-dependent pulmonary
toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat
Oncol Biol Phys 69, 350-357.
Richter, J., and Flentje, M. (2009). Zielvolumenkonzepte, Dosisspezifikation, Bestrahlungsplansysteme. In
Radioonkologie, Band 1 Grundlagen, M.M.a.H.S. M. Bamberg, ed. (München Wien New York: W.
Zuckschwerdt Verlag), pp. 143-152.
Rodrigues, G., Lock, M., D'Souza, D., Yu, E., and Van Dyk, J. (2004). Prediction of radiation pneumonitis by
dose - volume histogram parameters in lung cancer--a systematic review. Radiother Oncol 71, 127-138.
Rosenberg, S.A., and Kaplan, H.S. (1985). The evolution and summary results of the Stanford randomized
clinical trials of the management of Hodgkin's disease: 1962-1984. Int J Radiat Oncol Biol Phys 11, 5-22.
Rosenwald, A., and Küppers, R. (2010). Pathologie und molekulare Pathologie des Hodgkin-Lymphoms. Der
Onkologe 16, 9-17.
Rueffer, U., Josting, A., Franklin, J., May, M., Sieber, M., Breuer, K., Engert, A., and Diehl, V. (2001). Non-
Hodgkin's lymphoma after primary Hodgkin's disease in the German Hodgkin's Lymphoma Study Group:
incidence, treatment, and prognosis. J Clin Oncol 19, 2026-2032.
Santoro, A., Bonfante, V., and Bonadonna, G. (1982). Salvage chemotherapy with ABVD in MOPP-resistant
Hodgkin's disease. Ann Intern Med 96, 139-143.
Santoro, A., Viviani, S., Valagussa, P., Bonfante, V., and Bonadonna, G. (1986). CCNU, etoposide, and
prednimustine (CEP) in refractory Hodgkin's disease. Semin Oncol 13, 23-26.
Schellong, G., Potter, R., Bramswig, J., Wagner, W., Prott, F.J., Dorffel, W., Korholz, D., Mann, G., Rath, B.,
Reiter, A., Weissbach, G., Riepenhausen, M., Thiemann, M., and Schwarze, E.W. (1999). High cure rates and
reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian multicenter trial DAL-HD-90.
The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 17, 3736-3744.
132